Periprosthetic Joint Infection in Patients with Inflammatory Joint Disease: A Review of Risk Factors and Current Approaches to Diagnosis and Management
Restricted accessReview articleFirst published online July, 2013
Periprosthetic Joint Infection in Patients with Inflammatory Joint Disease: A Review of Risk Factors and Current Approaches to Diagnosis and Management
Prevention, early identification, and effective management of periprosthetic joint infection (PJI) in patients with inflammatory joint disease (IJD) present unique challenges for physicians. Discontinuing disease-modifying anti-rheumatoid drugs (DMARDs) perioperatively may reduce immunosuppression and infection risk at the expense of increasing disease flares. Interpreting traditional diagnostic markers of PJI can be difficult due to disease-related inflammation.
Purposes
This review is designed to answer how to (1) manage immunosuppressive/DMARD therapy perioperatively, (2) diagnose PJI in patients with IJD, and (3) treat PJI in this population.
Methods
The PubMed database was searched for relevant articles with subsequent review by independent authors.
Results
While there is evidence to support the use of methotrexate perioperatively in RA patients, it remains unclear whether using anti-tumor necrosis factor medications perioperatively increases the risk of surgical site infections. Serum erythrocyte sedimentation rate and C-reactive protein can be useful for diagnosis of PJI in this population, but only as part of comprehensive workup that ultimately relies upon sampling of joint fluid. Management of PJI depends on several clinical factors including duration of infection and the likelihood of biofilm presence, the infecting organism, sensitivity to antibiotic therapy, and host immune status. The evidence suggests that two-stage revision or resection arthroplasty is more likely to eradicate infection, particularly when MRSA is the pathogen.
Conclusion
Immunosuppression and baseline inflammatory changes in the IJD population can complicate the prevention, diagnosis, and treatment of PJI. Understanding the increase in risk associated with IJD and its treatment is essential for proper management when patients undergo lower extremity arthroplasty.
AuKReedGCurtisJHigh disease activity is associated with an increased risk of infection in patients with rheumatoid arthritisAnn Rheum Dis.201170785–79110.1136/ard.2010.128637
2.
BaréJMacdonaldSBourneRPreoperative Evaluations in Revision Total Knee ArthroplastyClin Orthop200644640–44
3.
BerbariEFOsmonDDuffyMCOutcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodesClin Infect Dis.200642216–22310.1086/498507
4.
BernardLLübbekeASternRBruJPFeronJMPeyramondDDenormandiePArvieuxCChirouzeCPerronneCHoffmeyePGroupe d'Etude sur l'OstéiteValue of peroperative investigation in diagnosing prosthetic joint infection: retrospective cohort study and literature reviewScan J Infect Dis200436410–41610.1080/00365540410015240
5.
BongartzTHalliganCOsmonDIncidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritisArthritis Rheum.2008591713–172010.1002/art.24060
6.
BreidahlWHNewmanJSTaljanovicMSAdlerRSPower Doppler sonography in the assessment of musculoskeletal fluid collectionAm J Roentgenol199616661444–144610.2214/ajr.166.6.8633460
7.
CiprianoCABrownNMMichaelAMMoricMSporerSMDellaVCSerum and synovial fluid analysis for diagnosing chronic periprosthetic infection in patients with inflammatory arthritisJ Bone Joint Surg Am.201294594–60010.2106/JBJS.J.01318
8.
Da CunhaBMaria Henrique Da MotaLDos Santos-NetoLRisk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alpha therapyInt J Rheumatol201220121–510.1155/2012/369565
9.
Della ValleCParviziJBauerTWAmerican Academy of Orthopaedic Surgeons clinical practice guideline on: the diagnosis of periprosthetic joint infections of the hip and kneeJ Bone Joint Surg Am.2011931355–135710.2106/JBJS.9314ebo
10.
Della ValleCJSporerSMJacobsJJBergerRARosenbergAGPaproskyWGPreoperative testing for sepsis before revision total knee arthroplastyJ Arthroplasty.20072290–9310.1016/j.arth.2007.04.013
11.
FahlénAEngstrandLBakerBSPowlesAFryLComparison of bacterial microviota in skin biopsies from normal and psoriatic skinArch Dermatol Res2012304115–2210.1007/s00403-011-1189-x
12.
GarciaRHardyBKraayMGoldbergVRevision total knee arthroplasty for aseptic and septic causes in patients with rheumatoid arthritisClin Orthop.201046882–8910.1007/s11999-009-1061-x
13.
GardnerJGioeTJTatmanPCan this prosthesis be saved? Implant salvage attempts in infected primary TKAClin Orthop20114694970–97610.1007/s11999-010-1417-2
14.
GreidanusNMasriBGarbuzDUse of erythrocyte sedimentation rate and C-reactive protein level to diagnose infection before revision total knee arthroplasty. A prospective evaluationJ Bone Joint Surg2007891409–141610.2106/JBJS.D.02602
15.
GrennanDMGrayJLoudonJFearSMethotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgeryAnn Rheum Dis.200160214–21710.1136/ard.60.3.214
16.
HiraoMHashimotoJTsuboiHLaboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumabAnn Rheum Dis.200968654–65710.1136/ard.2008.090068
17.
KerseyRBenjaminJMarsonBWhite blood cell counts and differential in synovial fluid of aseptically failed total knee arthroplastyJ Arthroplasty200015301–304
18.
KimYChoiYKimJTreatment based on the type of infected TKA improves infection controlClin Orthop.2011469977–98410.1007/s11999-010-1425-2
19.
KurtzSMLauEWatsonHSchmierJKParviziJEconomic burden of periprosthetic joint infection in the United StatesJ Arthroplasty20122761–5
20.
MasonJBFehringTOdumSGriffinWLNussmanDSThe value of white blood cell counts before revision total knee arthroplastyJ Arthroplasty2003181038–1043
21.
MenonTJWroblewskiBMCharnley low-friction arthroplasty in patients with psoriasisCli Orthop Relat Res.1983176127–128
22.
Momohara S, Hashimoto J, Tsuboi H et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol. 2012; doi: a10.1007/s10165-012-0683-0
23.
MomoharaSKawakamiKIwamotoTProsthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugsMod Rheumatol.201121469–47510.1007/s10165-011-0423-x
24.
Musculoskeletal Infection Society WorkgroupNew definition for periprosthetic joint infectionJ Arthroplasty.2011261136–113810.1016/j.arth.2011.09.026
25.
RanganathVKElashoffDAKhannaDAge adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patientsJ Rheumatol.2005321040–1042
26.
SaagKTengGPatkarNAmerican College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Rheum.200859762–78410.1002/art.23721
27.
ScanzelloCFiggieMNestorBGoodmanSPerioperative management of medications used in the treatment of rheumatoid arthritisHSS J20062141–14710.1007/s11420-006-9012-5
28.
SchinskyMDella ValleCSporerSPaproskyWPerioperative testing for joint infection in patients undergoing revision total hip arthroplastyJ Bone Joint Surg.2008901869–187510.2106/JBJS.G.01255
29.
SchramaJEspehaugBHallanGRisk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty RegisterArthritis Care Res.201062473–47910.1002/acr.20036
30.
SegawaHTsukayamaDTKyleRFBeckerDAGustiloRBInfection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infectionsJ Bone Joint Surg Am1999811434–1445
31.
SendiPBanderetFGraberPZimmerliWClinical comparison between exogenous and haematogenous periprosthetic joint infections caused by Staphylococcus aureusClin Microbiol Infect2011171098–110010.1111/j.1469-0691.2011.03510.x
32.
SpangehlMJMasriBAO'ConnellJXDuncanCPProspective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplastiesJ Bone Joint Surg Am199981672–683
33.
SreekumarRGrayJKayPGrennanDMMethotrexate and post operative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery—a ten year follow-upActa Orthop Belg201177823–826
34.
SternSHInsallJNWindsorREInglisAEDinesDMTotal knee arthroplasty in patients with psoriasisClin Orthop Relat Res1989248108–110
35.
TattevinPCrémieuxACPottierPHutenDCarbonCProsthetic joint infection: when can prosthesis salvage be considered?Clin Infect Dis199929292–29510.1086/520202
36.
TrampuzAHanssenAOsmonDMandrekarJSteckelbergJMPatelRSynovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infectionAm J Med2004117556–562
37.
YildirimKErdalAKarataySMelikoğluMAUğurMSenelKRelationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitisSouth Med J200497350–35310.1097/01.SMJ.0000066946.56322.3C
38.
YildirimKKarataySMelikogluMAGureserGUgurMSenelKAssociations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritisAnn Clin Lab Sci.200534423–426
